Table of Contents
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 18, 2005
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
(Commission File Number)
10275 Science Center Drive,
San Diego, California
(Address of principal executive offices)
San Diego, California
(Address of principal executive offices)
(858) 550-7500
(Registrant’s telephone number, including area code)
(Registrant’s telephone number, including area code)
77-0160744
(I.R.S. Employer Identification No.)
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
(Zip Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events | ||||||||
Item 9.01 Financial Statements And Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT 99.1 |
Table of Contents
Item 8.01 Other Events
On November 18, 2005 the registrant issued a press release regarding exploration of strategic alternatives. The press release is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements And Exhibits
(d) | Exhibits |
99.1 | Press release of the Company, dated November 18, 2005. |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned.
LIGAND PHARMACEUTICALS INCORPORATED | ||||
Date November 18, 2005 | By: | /s/ Warner R. Broaddus | ||
Name: | Warner R. Broaddus | |||
Title: | Vice President, General Counsel & Secretary | |||